Dr. Vivian Bi, Aclaris Therapeutics

wpadm — Mon, 26 Sep 2022 23:05:40 +0000

Dr. Vivian Bi is a Senior Director and Head of Pharmaceutical Development at Aclaris Therapeutics Inc., where she looks after the development of multiple pharmaceutical products from preclinical to phase IIb. She has held various positions at Pfizer Global R&D, Vertex Pharmaceuticals, AstraZeneca Pharmaceuticals and Ashland Specialty Ingredients before joining her current organization. Her research interests are oral and parenteral drug delivery systems for both small molecules and biologics. Dr. Bi has published over 50 research papers, abstracts and patents. She obtained her B.S. degree from Shenyang Pharmaceutical University in China, and completed her Ph.D. in Pharmaceutical Science from Meijo University in Japan.

Panel Discussion: Early Formulation Challenges and Solutions – Discovery to Phase I

The post Dr. Vivian Bi, Aclaris Therapeutics appeared first on Pharma Crystallization Summit.

Dr. John A. Grosso, Arvinas

wpadm — Mon, 26 Sep 2022 22:52:38 +0000

Dr. Grosso is the Senior Vice President of R&D Technical Operations at Arvinas Inc. He is responsible for active ingredient and drug product development, scale-up, manufacturing, and clinical supply logistics in support of Arvinas’ portfolio of PROTACS® (protein degraders) useful in the treatment of cancer and other diseases related to over-expression and protein mutation. He has developed a global supply chain encompassing over 20 CDMOs, spanning 8 countries and 3 continents and has transitioned development programs into commercial facilities for preparation of Ph3 supplies, validation and commercial launch.

Prior to joining Arvinas, Dr. Grosso was Executive Director and Head of Pharmaceutical Development at Vitae Pharmaceuticals where he was responsible for API and DP development and manufacturing as well as Clinical Supply. During the two years spent at Vitae, he advanced two oral RORƴt antagonists and one LXR agonist into the clinic.

Dr. Grosso began his career with Bristol-Myers Squibb in Chemical Process R&D rising to the level of Director and site-head for PR&D over a twenty-year span. He transitioned into Analytical R&D where, as Executive Director, he was responsible for process analytical science, method development and testing for both API and DP, in addition to a number of specialty labs. He finished his tenure at BMS as Executive Director, Drug Product Science and Technology. Over his 32-year career at BMS he played a pivotal role in the development and commercialization of Monopril®, Taxol®, Eliquis®, Sprycel®, and Dapagliflozin®

Dr. Grosso earned his undergraduate degree in Chemistry at New York University, and his Ph.D. in Medicinal Chemistry at Purdue University.

Panel Discussions: Early Formulation Challenges and Solutions – Discovery to Phase I

The post Dr. John A. Grosso, Arvinas appeared first on Pharma Crystallization Summit.

3) Early Formulation Challenges – Discover to Phase I Archives - Pharma Crystallization Summit

Dr. Vivian Bi, Aclaris Therapeutics

Dr. John A. Grosso, Arvinas